Cellectar Biosciences's EBIT per Share for the
three
months ended in Dec. 2023 was $-0.83.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.18.
During the past 3 years, the average EBIT per Share Growth Rate was 25.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 39.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 53.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Cellectar Biosciences's EBIT per Share or its related term are showing as below:
CLRB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 25.5 Med: 53.95 Max: 66.7
Current: 25.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Cellectar Biosciences was 66.70% per year. The lowest was 25.50% per year. And the median was 53.95% per year.
CLRB's 3-Year EBIT Growth Rate is ranked better than 77.2% of 1307
companies
in the Biotechnology industry
Industry Median: 3.4
vs CLRB: 25.50
Cellectar Biosciences EBIT per Share Historical Data
The historical data trend for Cellectar Biosciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences (NAS:CLRB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Cellectar Biosciences EBIT per Share Related Terms
Thank you for viewing the detailed overview of Cellectar Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Cellectar Biosciences (Cellectar Biosciences) Business Description
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLRB has been successfully added to your 